AbbVie - ABBV Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

16 brokers have issued 1-year price targets for AbbVie's stock. Their ABBV share price forecasts range from $140.00 to $200.00. On average, they predict the company's stock price to reach $161.12 in the next year. This suggests a possible upside of 2.0% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $161.61 on January 1st, 2023. Since then, ABBV stock has decreased by 2.2% and is now trading at $157.98.
View the best growth stocks for 2023 here.

AbbVie saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 12,700,000 shares, an increase of 8.5% from the February 13th total of 11,710,000 shares. Based on an average daily volume of 5,620,000 shares, the short-interest ratio is currently 2.3 days.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings data on Thursday, February, 9th. The company reported $3.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.54 by $0.06. The company earned $15.12 billion during the quarter, compared to analyst estimates of $15.30 billion. AbbVie had a trailing twelve-month return on equity of 154.52% and a net margin of 20.39%. AbbVie's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.31 EPS.
Read the conference call transcript.

AbbVie declared a quarterly dividend on Thursday, February 16th. Investors of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. This represents a $5.92 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, April 13th.
Read our dividend analysis for ABBV.

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), iShares Core High Dividend ETF (HDV), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), VanEck Pharmaceutical ETF (PPH), Sound Equity Income ETF (SDEI), Kelly CRISPR & Gene Editing Technology ETF (XDNA) and iShares U.S. Healthcare ETF (IYH).

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.75%. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 89.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie issued an update on its FY 2024 earnings guidance on Friday, February, 10th. The company provided earnings per share (EPS) guidance of $10.70- for the period. The company issued revenue guidance of -.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $157.98.

AbbVie (NYSE:ABBV) has a market capitalization of $278.70 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.